Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Show other versions (1)

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instea...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Davies, C, Pan, H, Gray, R, Collins, R, Delmestri, A, Wang, Y, Peto, R, Godwin, J, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Khaled, H, Bonfill, X, Tort, S, Urrútia, G, Bradbury, J, Davis, SR, Clarke, M, Forbes, J, Haddad, P, Hou, M, Inbar, M, Kielanowska, J
פורמט: Journal article
יצא לאור: 2013

פריטים דומים

פריטים דומים